BG105643A - Carboxylic acids and carboxylic acid isosteres of n-heterocycle compounds - Google Patents

Carboxylic acids and carboxylic acid isosteres of n-heterocycle compounds

Info

Publication number
BG105643A
BG105643A BG105643A BG10564301A BG105643A BG 105643 A BG105643 A BG 105643A BG 105643 A BG105643 A BG 105643A BG 10564301 A BG10564301 A BG 10564301A BG 105643 A BG105643 A BG 105643A
Authority
BG
Bulgaria
Prior art keywords
treating
carboxylic acid
acid isosteres
carboxylic acids
heterocycle compounds
Prior art date
Application number
BG105643A
Other languages
Bulgarian (bg)
English (en)
Inventor
Gregory Hamilton
Mark Norman
Yong-Qian Wu
Original Assignee
Gpi Nil Holdings, Inc
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gpi Nil Holdings, Inc, Amgen Inc. filed Critical Gpi Nil Holdings, Inc
Publication of BG105643A publication Critical patent/BG105643A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
BG105643A 1998-12-03 2001-06-25 Carboxylic acids and carboxylic acid isosteres of n-heterocycle compounds BG105643A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20423798A 1998-12-03 1998-12-03
US09/453,571 US6331537B1 (en) 1998-06-03 1999-12-02 Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
PCT/US1999/028663 WO2000032588A2 (en) 1998-12-03 1999-12-03 Carboxylic acids and carboxylic acid isosteres of n-heterocyclic compounds

Publications (1)

Publication Number Publication Date
BG105643A true BG105643A (en) 2002-02-28

Family

ID=26899306

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105643A BG105643A (en) 1998-12-03 2001-06-25 Carboxylic acids and carboxylic acid isosteres of n-heterocycle compounds

Country Status (20)

Country Link
US (2) US6331537B1 (de)
EP (1) EP1135370B1 (de)
KR (1) KR20010086080A (de)
CN (1) CN1213026C (de)
AT (1) ATE252078T1 (de)
AU (1) AU767468B2 (de)
BG (1) BG105643A (de)
BR (1) BR9916461A (de)
CA (1) CA2353460C (de)
CZ (1) CZ20011971A3 (de)
DE (1) DE69912151T2 (de)
EA (1) EA003926B1 (de)
HU (1) HUP0105027A3 (de)
IL (1) IL143392A0 (de)
MX (1) MXPA01005549A (de)
NO (1) NO318909B1 (de)
NZ (1) NZ511673A (de)
PL (1) PL348715A1 (de)
SK (1) SK7442001A3 (de)
WO (1) WO2000032588A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US20010049381A1 (en) * 1997-06-04 2001-12-06 Gpl Nil Holdings, Inc., Pyrrolidine derivative hair growth compositions and uses
US6274602B1 (en) * 1998-06-03 2001-08-14 Gpi Nil Holdings, Inc. Heterocyclic thioester and ketone hair growth compositions and uses
AU742040C (en) * 1997-09-24 2003-10-02 Amgen, Inc. Method for preventing and treating hearing loss using sensorineurotrophic compounds
BR0012327A (pt) 1999-07-09 2002-07-02 Ortho Mcneil Pharm Inc Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados
DOP2000000107A (es) 1999-12-01 2002-09-16 Agouron Pharmaceutical Inc Compuestos, composiciones y metodos para estimular el crecimiento y alongamiento de las neuronas
US6809093B2 (en) * 2000-10-17 2004-10-26 H. Lee Moffitt Cancer & Research Institute, Inc. 2-substituted heterocyclic compounds
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
ATE408593T1 (de) 2001-05-03 2008-10-15 Galileo Lab Inc Pyruvatderivate
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
JP2005500270A (ja) * 2001-05-29 2005-01-06 ギルフォード ファーマシュウティカルズ インコーポレイテッド 手術の結果として発生した神経損傷を治療するための方法
US20100030301A1 (en) * 2001-11-09 2010-02-04 Cochlear Limited Electrical stimulation for modulation of neural plasticity
AUPR879201A0 (en) * 2001-11-09 2001-12-06 Cochlear Limited Subthreshold stimulation of a cochlea
US20100030130A1 (en) * 2001-11-09 2010-02-04 Cochlear Limited Pharmaceutical intervention for modulation of neural plasticity
US20050171579A1 (en) * 2001-11-09 2005-08-04 Claudia Tasche Stimulating device
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
CN101845009B (zh) 2002-07-29 2012-10-03 卡达克斯药物公司 用于抑制和改善疾病的类胡萝卜素结构类似物
US7320997B2 (en) 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US7345091B2 (en) 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
AU2003259846A1 (en) * 2002-08-16 2004-03-03 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
US20040180880A1 (en) * 2002-10-03 2004-09-16 Lauffer David J. Piperazine and piperidine derivatives
CA2564066A1 (en) * 2004-04-14 2005-11-03 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
CA2569724A1 (en) 2004-06-15 2005-12-29 Cochlear Americas Automatic determination of the threshold of an evoked neural response
US20060116423A1 (en) * 2004-10-18 2006-06-01 Dash Pramod K Methods and compositions for treatment of central nervous system injury with isothiocyanates
JP2008521831A (ja) * 2004-11-30 2008-06-26 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
KR20080000665A (ko) 2005-04-22 2008-01-02 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 디펩티딜 펩티다아제-ⅳ 억제제
WO2006138187A1 (en) * 2005-06-13 2006-12-28 Yong-Qian Wu Enhanced tissue penetration prodrugs
WO2007030559A2 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. 1, 3-disubstituted indole derivatives for use as ppar modulators
DE102005050377A1 (de) * 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
RU2470910C9 (ru) 2007-06-29 2013-05-20 Акьюсела, Инк. Соединения, представляющие собой алкинилфенильные производные, для лечения офтальмических заболеваний и расстройств
CN103553945B (zh) 2007-10-05 2015-01-07 奥克塞拉有限公司 用于治疗疾病的烷氧基化合物
MY156662A (en) 2007-11-01 2016-03-15 Acucela Inc Amine derivative compounds for treating ophthalmic diseases and disorders
AU2009239778B2 (en) 2008-04-24 2014-03-13 F2G Ltd Pyrrole antifungal agents
US9623000B2 (en) 2008-07-31 2017-04-18 Dekel Pharmaceuticals Ltd Compositions and methods for treating inflammatory disorders
JP5773877B2 (ja) 2008-10-22 2015-09-02 アキュセラ インコーポレイテッド 眼の疾患及び障害を治療する化合物
US20100317711A1 (en) * 2008-12-17 2010-12-16 Gliamed, Inc. Stem-like cells and method for reprogramming adult mammalian somatic cells
JP5860398B2 (ja) * 2009-07-02 2016-02-16 アキュセラ インコーポレイテッド 視覚サイクルモジュレーターの薬理
US9981018B2 (en) * 2010-06-08 2018-05-29 The Cleveland Clinic Foundation Compositions and methods for modulating toll-like receptor 2 activation
EP2804605A4 (de) 2012-01-20 2015-07-08 Acucela Inc Substituierte heterocyclische verbindungen zur behandlung von krankheiten
EP2822931B1 (de) 2012-03-09 2017-05-03 Inception 2, Inc. Triazolonverbindungen und verwendungen davon
SG11201504622PA (en) 2012-12-20 2015-07-30 Inception 2 Inc Triazolone compounds and uses thereof
CN105579440A (zh) 2013-09-06 2016-05-11 因森普深2公司 三唑酮化合物及其应用
EP3096755A4 (de) * 2014-01-23 2017-12-27 Sova Pharmaceuticals, Inc. Cystathionin-(gamma)-lyase (cse)-inhibnitoren zur behandlung von schmerzen
DK3221308T3 (en) 2014-11-21 2018-12-10 F2G Ltd Antifungals
MX2018001843A (es) * 2015-08-13 2018-05-16 River Town Therapeutics Inc Composiciones y metodos para tratar alopecia.
US10285977B2 (en) * 2015-08-13 2019-05-14 David Weinstein Consulting, Inc. Compositions and methods for treating alopecia
US20170266157A1 (en) * 2016-03-21 2017-09-21 David Weinstein Methods for wound healing and scar prevention
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
US10709686B2 (en) * 2018-03-20 2020-07-14 David Weinstein Consulting, Inc. Methods for treating pulmonary fibrosis
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
US20220265668A1 (en) * 2019-07-25 2022-08-25 Sensorion Treatment and/or prevention of lesions in the central auditory nervous system

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA794723B (en) 1978-09-11 1980-08-27 Univ Miami Anti-hypertensive agents
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
IT1148775B (it) 1980-02-29 1986-12-03 Attilio Pronzati Bastoncini da sci dotati di rotelle intercambiabili
US4692458A (en) 1980-03-05 1987-09-08 University Of Miami Anti-hypertensive agents
US4734420A (en) 1980-03-05 1988-03-29 University Of Miami Anti-hypertensive agents
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
GR75019B (de) 1980-09-17 1984-07-12 Univ Miami
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US5348944A (en) 1980-10-23 1994-09-20 Schering Corporation Carboxyalkyl dipeptides
LU88621I2 (fr) 1980-10-23 1995-09-01 Schering Corp Sandopril
US4766110A (en) * 1981-08-21 1988-08-23 Ryan James W Novel complex amido and imido derivatives of carboxyalkyl peptides
ZA826022B (en) 1981-08-21 1983-08-31 Univ Miami Novel complex amido and imido derivatives of carboxyalkyl peptides and thioethers and ethers of peptides
EP0088350B1 (de) 1982-03-08 1985-02-20 Schering Corporation Carboxyalkyl-Dipeptiden, Verfahren zu deren Herstellung und deren pharmazeutische Zusammensetzungen
US4431644A (en) 1982-03-08 1984-02-14 Schering Corporation Antihypertensive agents
EP0177581A4 (de) 1984-04-06 1987-08-10 Gail S Bazzano Zusammensetzungen für haarwachstum.
US4595766A (en) 1984-10-26 1986-06-17 Ciba-Geigy Corporation Process for the preparation of an indoline carboxylic acid
DE3508251A1 (de) 1985-03-08 1986-09-11 Merck Patent Gmbh, 6100 Darmstadt Dipeptide
CN86101850A (zh) 1985-03-22 1987-02-04 森得克斯(美国)有限公司 N，n′-二烷基胍基二肽的制造方法与用途
US5472687A (en) 1985-07-18 1995-12-05 Proctor; Peter H. Topical pyridine N-oxides
US5714510A (en) 1985-07-18 1998-02-03 Proctor; Peter H. Topical proxyl composition and method
WO1988000040A1 (en) 1986-07-02 1988-01-14 American Health Products Corporation Topical hair growing composition and kit
US5214034A (en) 1986-09-26 1993-05-25 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system containing the same
DE3636278A1 (de) 1986-10-24 1988-05-05 Hoechst Ag Herbizide mittel auf der basis von cyclischen (alpha)-iminocarbon-saeureaniliden sowie neue (alpha)-iminocarbonsaeureanilide und verfahren zu ihrer herstellung
IT1206078B (it) 1987-06-03 1989-04-14 Polifarma Spa Procedimento per la produzione di acido 3-indolpiruvico e suoi derivati loro uso farmaceutico
WO1989006234A1 (en) 1987-12-28 1989-07-13 Bazzano Gail S N,n-substituted amines and use thereof in hair growth promotion
US5187156A (en) 1988-03-16 1993-02-16 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
US5232923A (en) 1988-03-18 1993-08-03 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives and pharmaceutical preparations containing same
US5274097A (en) 1988-04-19 1993-12-28 Bayer Aktiengesellschaft 1,3-disubstituted pyrrolidines
IL90872A0 (en) 1988-07-08 1990-02-09 Smithkline Beckman Corp Retroviral protease binding peptides
US5002962A (en) 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5166317A (en) 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
EP0378318A1 (de) 1989-01-11 1990-07-18 Merck & Co. Inc. Verfahren zur Herstellung von FK-506 sowie Tricarbonylzwischenprodukten
US5359138A (en) 1989-04-15 1994-10-25 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Poststatin and related compounds or salts thereof
US5164525A (en) 1989-06-30 1992-11-17 Merck & Co., Inc. Synthetic process for fk-506 type macrolide intermediates
US5128483A (en) 1989-07-19 1992-07-07 American Cyanamid Company Dibromovinyl and acetylene-1-pyrrolidinecarboxylic acid intermediates
US5215969A (en) 1989-08-11 1993-06-01 Hahnemann University Dopaminergic neurotrophic factor for treatment of Parkinson's disease
US5703088A (en) 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5115098A (en) 1990-02-28 1992-05-19 President And Fellows Of Harvard College End-blocked peptides inhibiting binding capacity of gp120
JPH04211648A (ja) 1990-07-27 1992-08-03 Nippon Kayaku Co Ltd ケト酸アミド誘導体
DE4015255A1 (de) 1990-05-12 1991-11-14 Hoechst Ag Oxalyl-aminosaeurederivate, verfahren zu ihrer herstellung und ihrer verwendung als arzneimittel zur inhibierung der prolyl-hydroxylase
US5504197A (en) 1990-06-20 1996-04-02 The Salk Institute For Biological Studies DNA encoding neurotrophic growth factors
US5192773A (en) 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
ES2104597T3 (es) 1990-08-14 1997-10-16 Kenneth M Hallam Composicion para la promocion del crecimiento del cabello.
AU8727491A (en) 1990-08-29 1992-03-30 Vertex Pharmaceuticals Incorporated Modified di- and tripeptidyl immunosuppressive compounds
GB2247456A (en) 1990-09-03 1992-03-04 Fujisawa Pharmaceutical Co Tetrahydropyrane compounds, a process for their production and a pharmaceutical composition containing the same
JPH04124198A (ja) 1990-09-12 1992-04-24 Sumitomo Pharmaceut Co Ltd 神経栄養ペプチド誘導体
DE69118826T2 (de) 1990-11-27 1996-11-14 Fuji Photo Film Co Ltd Propenamidderivate, deren Polymere, Copolymere und deren Verwendung
AU9049391A (en) 1990-12-20 1992-07-22 Warner-Lambert Company 2-acylamido derivatives of 3,4-dihydro-3-oxo-quinoxaline having pharmaceutical activity
CA2098609A1 (en) 1990-12-28 1992-06-29 Raymond T. Bartus Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
FR2671082B1 (fr) 1990-12-28 1993-04-16 Oreal Agent a plusieurs composants ou kit de preparation de la forme sulfo-conjuguee de composes pyrimidino- ou triazino-n-oxyde et procede de mise en óoeuvre.
US5321009A (en) 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5147877A (en) 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
AU2007192A (en) 1991-05-08 1992-12-21 Vertex Pharmaceuticals Incorporated Rfkbp: a novel prolyl isomerase and rapamycin/fk506 binding protein
KR100244372B1 (ko) 1991-05-09 2000-03-02 조슈아 에스.보저 신규한 면역 억제성 화합물
US5620971A (en) 1991-05-09 1997-04-15 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
MX9202466A (es) 1991-05-24 1994-06-30 Vertex Pharma Compuestos inmunosupresores novedosos.
FR2677884B1 (fr) 1991-06-20 1993-07-09 Oreal Composition pour freiner la chute des cheveux a base de pyrimidines n-oxyde trisubstitues ou leurs derives sulfoconjugues, nouveaux composes pyrimidines n-oxyde ou leurs derives sulfoconjugues.
JPH05194235A (ja) 1991-07-25 1993-08-03 Tanabe Seiyaku Co Ltd 中枢性カルシウム拮抗剤
JPH05178824A (ja) 1991-08-05 1993-07-20 Takeda Chem Ind Ltd アスパラギン誘導体およびその用途
US5604294A (en) 1991-09-05 1997-02-18 Luly; Jay R. Macrocyclic immunomodulators
ZA929869B (en) 1991-12-20 1994-06-20 Syntex Inc Hiv protease inhibitors
GB9200245D0 (en) 1992-01-07 1992-02-26 British Bio Technology Compounds
WO1993014762A1 (en) 1992-01-27 1993-08-05 Merck & Co., Inc. 17β-HYDROXYBENZOYL-4-AZA-5α-ANDROST-1-EN-3-ONES USEFUL TO TREAT BALDNESS
WO1993018736A1 (fr) 1992-03-19 1993-09-30 Armand Pardo Compositions cosmetiques capillaires destinees aux traitements contre la chute des cheveux
CA2091194A1 (en) 1992-04-08 1993-10-09 Richard D. Connell 2-oxo-ethyl derivatives as immunosuppressants
US5342942A (en) 1992-06-09 1994-08-30 Warner-Lambert Company Pyrazoloquinazolone derivatives as neurotrophic agents
GB9216329D0 (en) 1992-07-31 1992-09-16 Erba Carlo Spa 17beta-substituted 4-aza-5alpha-androstan-3-one derivatives
DE4228455A1 (de) 1992-08-26 1994-09-15 Beiersdorf Ag Kosmetische und dermatologische Lichtschutzformulierungen mit einem Gehalt an Thiolen und/oder Thiolderivaten
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
NZ314207A (en) 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
EP0670309A1 (de) 1992-11-20 1995-09-06 Japan Tobacco Inc. Verbindung mit prolye-endopeptidase inhibierender aktivität und ihre pharmazeutische verwendung
WO1994013629A1 (en) 1992-12-11 1994-06-23 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
US5411991A (en) 1992-12-22 1995-05-02 Shander; Douglas Method of reducing hair growth employing sulfhydryl active compounds
US5646167A (en) 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5264619B1 (en) 1993-01-15 1996-05-14 Cosmos Pharm Corp Anti-androgenic cyclo and bicyclo alkenes
ATE172985T1 (de) 1993-02-09 1998-11-15 Bayer Ag Sulfonamidaminomethylenderivate als immunsuppressiva
WO1994021253A1 (en) 1993-03-17 1994-09-29 Abbott Laboratories Substituted aliphatic amine-containing macrocyclic immunomodulators
JP3599287B2 (ja) 1993-04-28 2004-12-08 三菱化学株式会社 スルホンアミド誘導体
US5319098A (en) * 1993-05-18 1994-06-07 Celgene Corporation Process for the stereoselective preparation of L-alanyl-L-proline
US5846981A (en) 1993-05-28 1998-12-08 Gpi Nil Holdings Inc. Inhibitors of rotamase enzyme activity
US5798355A (en) 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
HUT73100A (en) 1993-07-16 1996-06-28 Harvard College Regulated apoptosis
IT1270882B (it) 1993-10-05 1997-05-13 Isagro Srl Oligopeptidi ad attivita' fungicida
EP0748221B1 (de) 1993-11-04 1999-04-14 Merck & Co. Inc. 7-substituierte-4-aza-steroid-derivate als 5-alpha-reductase-hemmer
CA2152822A1 (en) 1993-11-04 1995-05-11 William R. Baker Cyclobutane derivatives as inhibitors of squalene synthetase and protein farnesyltransferase
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5612350A (en) 1993-11-30 1997-03-18 Abbott Laboratories Macrocyclic immunomodulators with novel cyclohexyl ring replacements
US5744485A (en) 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
US5898029A (en) 1994-04-12 1999-04-27 The John Hopkins University Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
AU2825295A (en) 1994-06-13 1996-01-05 Arcturus Pharmaceutical Corporation Method for the treatment, prevention or minimization of hair loss
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6057119A (en) 1994-06-17 2000-05-02 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1β converting enzyme
DE4425950A1 (de) 1994-07-21 1996-01-25 Bayer Ag Verwendung von Sulfonylbenzyl-substituierten Imidazolen, Imidazopyridinen und Benzimidazolen
DE69534300T2 (de) * 1994-08-18 2006-05-18 Ariad Gene Therapeutics, Inc., Cambridge Neues multimerisierendes reagenz
AU3079295A (en) 1994-09-01 1996-03-22 Universidad Complutense De Madrid New arylpiperazine derivatives
US5543423A (en) 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
IL115685A (en) 1994-11-16 2000-08-31 Vertex Pharma Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
US5621108A (en) 1994-12-05 1997-04-15 Trustees Of The University Of Pennsylvania Processes and intermediates for preparing macrocycles
US5863902A (en) 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US5804560A (en) 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5726184A (en) 1995-05-19 1998-03-10 Vertex Pharmaceuticals Incorporated Tetralin compounds with improved MDR activity
US6291510B1 (en) * 1995-06-07 2001-09-18 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5859031A (en) 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5696135A (en) 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5614547A (en) 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US6037370A (en) 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5801197A (en) 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5646180A (en) 1995-12-05 1997-07-08 Vertex Pharmaceuticals Incorporated Treatment of the CNS effects of HIV
AU1463997A (en) 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
AU731826B2 (en) * 1996-02-28 2001-04-05 Ariad Pharmaceuticals, Inc. Synthetic Multimerizing Agents
US5717092A (en) 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity
US5905076A (en) 1996-04-10 1999-05-18 National Research Council Of Canada 6-substituted amino-4-oxa-1-azabicyclo 3,2,0! heptan-7-one derivatives as cysteine protease inhibitors
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
GB9612884D0 (en) 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds
EP0912550A1 (de) 1996-06-25 1999-05-06 Smithkline Beecham Plc Sulfonamide derivatives als 5ht7 rezeptor antagoniste
TW397809B (en) 1996-08-09 2000-07-11 Takeda Chemical Industries Ltd Dimethylpropanediol compounds
KR100339296B1 (ko) 1996-08-28 2002-06-03 데이비드 엠 모이어 헤테로고리성 메탈로프로테아제 억제제
US5786378A (en) 1996-09-25 1998-07-28 Gpi Nil Holdings, Inc. Heterocyclic thioesters
US5801187A (en) * 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
US5780484A (en) 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5840736A (en) 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5811434A (en) 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
AU4966497A (en) 1996-11-18 1998-06-10 Yamanouchi Pharmaceutical Co., Ltd. Novel acylamino-substituted acylanilide derivatives or pharmaceutical composition comprising the same
EP0944645B1 (de) 1996-12-06 2005-03-09 Vertex Pharmaceuticals Incorporated INHIBITOREN DES INTERLEUKIN-1beta KONVERTIERENDEN ENZYMS
US5874449A (en) 1996-12-31 1999-02-23 Gpi Nil Holdings, Inc. N-linked sulfonamides of heterocyclic thioesters
US5935989A (en) 1996-12-31 1999-08-10 Gpi Nil Holdings Inc. N-linked ureas and carbamates of heterocyclic thioesters
US5721256A (en) 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
US5846979A (en) * 1997-02-28 1998-12-08 Gpi Nil Holdings, Inc. N-oxides of heterocyclic esters, amides, thioesters, and ketones
US5945441A (en) * 1997-06-04 1999-08-31 Gpi Nil Holdings, Inc. Pyrrolidine carboxylate hair revitalizing agents
AU766579B2 (en) 1997-08-29 2003-10-16 Vertex Pharmaceuticals Incorporated Compounds possessing neuronal activity
AU742040C (en) * 1997-09-24 2003-10-02 Amgen, Inc. Method for preventing and treating hearing loss using sensorineurotrophic compounds
GB9804426D0 (en) 1998-03-02 1998-04-29 Pfizer Ltd Heterocycles
EA008723B1 (ru) * 1998-06-03 2007-06-29 Джи-Пи-Ай Эн-Ай-Эл Холдингз, Инк. Аза-гетероциклические соединения, применяемые для лечения неврологических расстройств и выпадения волос
US6284779B1 (en) * 1999-02-03 2001-09-04 Schering Aktiiengesellschaft Heteroaromatic compounds

Also Published As

Publication number Publication date
HUP0105027A3 (en) 2002-10-28
HUP0105027A2 (hu) 2002-05-29
CA2353460A1 (en) 2000-06-08
DE69912151D1 (de) 2003-11-20
KR20010086080A (ko) 2001-09-07
US20030186961A1 (en) 2003-10-02
EP1135370A2 (de) 2001-09-26
WO2000032588A2 (en) 2000-06-08
US7153883B2 (en) 2006-12-26
DE69912151T2 (de) 2004-07-08
ATE252078T1 (de) 2003-11-15
CN1213026C (zh) 2005-08-03
BR9916461A (pt) 2001-09-04
NZ511673A (en) 2004-03-26
EA003926B1 (ru) 2003-10-30
EA200100570A1 (ru) 2001-12-24
NO20012765L (no) 2001-07-20
CZ20011971A3 (cs) 2001-09-12
AU767468B2 (en) 2003-11-13
NO20012765D0 (no) 2001-06-05
SK7442001A3 (en) 2001-12-03
MXPA01005549A (es) 2003-07-14
IL143392A0 (en) 2002-04-21
US6331537B1 (en) 2001-12-18
EP1135370B1 (de) 2003-10-15
WO2000032588A3 (en) 2001-02-22
CA2353460C (en) 2009-11-10
PL348715A1 (en) 2002-06-03
CN1330634A (zh) 2002-01-09
NO318909B1 (no) 2005-05-23
AU1841300A (en) 2000-06-19

Similar Documents

Publication Publication Date Title
BG105643A (en) Carboxylic acids and carboxylic acid isosteres of n-heterocycle compounds
BG105012A (en) N-linked sulphonamides of n-heterocyclic carboxylic acids or carboxylic isosteres
ATE319712T1 (de) Hydantoin derivate, pharmazeutische zusammensetzungen und verfahren zu ihrer verwendung
MX9604985A (es) Cardiotropina y usos de la misma.
RU93049265A (ru) Производные декагидроизохинолинов, способ получения, фармацевтическая композиция
MY115977A (en) Synthetic excitatory amino acids
UA49011C2 (uk) Похідні циклічної амінокислоти, фармацевтична композиція та спосіб лікування
AP2002002596A0 (en) Piperazine and piperidine derivatives.
EA200500007A1 (ru) Пролекарства возбуждающих аминокислот
ATE325610T1 (de) Xanthinderivative zur behandlung von hirnischämie
MX9701820A (es) Compuestos de pirazolo [3,4-g] quinoxalina que inhiben proteina tirosina quinasa receptora de pdgf.
NZ508462A (en) Aza-heterocyclic compounds used to treat neurological disorders and hair loss
BG105014A (en) Ureas and carbamates of n-heterocyclic carboxylic acids and carboxylic acid isosteres
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
BR9815919A (pt) Compostos aza heterocìclicos usados para tratar distúrbios neurológicos e perda de cabelo
CA2296560A1 (en) Amino acid derivatives useful to treat stroke
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
CA2261259A1 (en) Alpha-amino acid amides, preparation thereof and the therapeutical use thereof
WO2002005798A3 (en) Pharmaceutical compositions for treating neurological disorders
PL336897A1 (en) Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts
WO2002055481A8 (en) Prodrugs of excitatory amino acids
WO2003006489A3 (en) Prodrugs of excitatory amino acids
WO2003037261A3 (en) Methods and compositions for the treatment and diagnosis of pain disorders using 9805
WO2000011137A8 (en) Acid labile cationic amphiphiles
BG102864A (en) Application of phosphonic acid esters for the treatment of functional disorders of the brain and depressions